优化犬类T细胞的激活,扩张和转导.
Treyvon W Davis1, Jennifer C Holmes2, Arissa He3
1Department of Biological Sciences, College of Veterinary Medicine, North Carolina State University, North Carolina, Raleigh, United States of America.
PloS one
|September 11, 2025
概括
优化犬类T细胞免疫疗法需要有效的T细胞激活. 板结合抗体,特别是αCD3克隆CA17.6F9与αCD28克隆5B8或PMA/ionomycin,增强T细胞激活,扩张和转导,以获得更好的癌症治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 兽医瘤学 兽医瘤学
- 细胞疗法细胞疗法
背景情况:
- 狗作为人类癌症研究的有价值的模型.
- 狗T细胞免疫疗法显示出前景,但受到亚最佳T细胞激活和转导方法的限制.
- 现有的研究缺乏对不同抗体刺激策略和表现方法进行全面的比较,用于犬类T细胞.
研究的目的:
- 确定用于免疫治疗的犬类T细胞激活,扩张和病毒转导的最有效方法.
- 为了比较板结合抗体与珠结合抗体对T细胞刺激的疗效.
- 评估不同的抗体克隆组合和辅原体,以优化犬类T细胞反应.
主要方法:
- 测试了12种抗体刺激策略,包括两种αCD3和两种αCD28抗体克隆的组合,呈现在盘子或珠子上.
- 评估了两种辅激素:醇米里酸盐 (PMA) 与离子素和康卡纳瓦林A (ConA).
- 评估了刺激策略对T细胞激活,扩张,转导效率,CD4/CD8T细胞亚群比例和调控性T细胞 (Treg) 流行的影响.
主要成果:
- 板块结合抗体在犬类T细胞刺激方面明显比珠子结合抗体更有效.
- 板结合的αCD3克隆CA17.6F9与αCD28克隆5B8相结合,或与基因PMA/ionomycin相结合,产生了优异的激活,扩张和转导.
- 这些最佳策略还导致了有利的T细胞亚群概况,包括CD4/CD8比率和Treg患病率,可能改善治疗结果.
结论:
- 板结合抗体刺激,特别是使用特定的αCD3/αCD28组合或PMA/ionomycin,对于犬类T细胞免疫疗法来说是优越的.
- 优化的T细胞激活和转导策略可以提高基于T细胞的癌症治疗在狗中的有效性和安全性.
- 这些发现为推进犬类T细胞免疫疗法提供了关键的基础,对人类癌症疗法有潜在的影响.
相关概念视频
T Cell Activation and Clonal Selection
14.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.8K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K


